Teva Pharmaceutical (Four Oncology R&D Assets) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Teva Pharmaceutical (Four Oncology R&D Assets) General Information

Description

Four oncology development programs of Teva Pharmaceutical Industries. The business assets are CEP-32496, a potent small molecule inhibitor of BRAF, EGFR and RET, CEP-40783, a potent, highly selective, pseudo-irreversible inhibitor of AXL and cMET, CEP-40125, a nanoformulation of a modified bendamustine with potential activity in solid tumors and TEV-44229, a potent, selective inhibitor of the atypical kinase PKCiota that is in preclinical studies.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • San Diego, CA 92121
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Drug Discovery
Acquirer
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • San Diego, CA 92121
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Teva Pharmaceutical (Four Oncology R&D Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.

Request a free trial

Teva Pharmaceutical (Four Oncology R&D Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Teva Pharmaceutical (Four Oncology R&D Assets)‘s full profile, request access.

Request a free trial

Teva Pharmaceutical (Four Oncology R&D Assets) FAQs

  • Where is Teva Pharmaceutical (Four Oncology R&D Assets) headquartered?

    Teva Pharmaceutical (Four Oncology R&D Assets) is headquartered in San Diego, CA.

  • What industry is Teva Pharmaceutical (Four Oncology R&D Assets) in?

    Teva Pharmaceutical (Four Oncology R&D Assets)’s primary industry is Buildings and Property.

  • Is Teva Pharmaceutical (Four Oncology R&D Assets) a private or public company?

    Teva Pharmaceutical (Four Oncology R&D Assets) is a Private company.

  • What is the current valuation of Teva Pharmaceutical (Four Oncology R&D Assets)?

    The current valuation of Teva Pharmaceutical (Four Oncology R&D Assets) is .

  • What is Teva Pharmaceutical (Four Oncology R&D Assets)’s current revenue?

    The current revenue for Teva Pharmaceutical (Four Oncology R&D Assets) is .

  • Who are Teva Pharmaceutical (Four Oncology R&D Assets)’s investors?

    Teva Pharmaceutical Industries has invested in Teva Pharmaceutical (Four Oncology R&D Assets).

  • When was Teva Pharmaceutical (Four Oncology R&D Assets) acquired?

    Teva Pharmaceutical (Four Oncology R&D Assets) was acquired on 17-Mar-2015.

  • Who acquired Teva Pharmaceutical (Four Oncology R&D Assets)?

    Teva Pharmaceutical (Four Oncology R&D Assets) was acquired by Ignyta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »